Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of WuXi PharmaTech, China's top contract research organization, has spelled out for the first time in detail how its ill-timed acquisition of an American biologics manufacturing and testing outfit, lashed by the tempests of the West's financial crisis, triggered a massive loss that wiped out five years of earnings

You may also be interested in...



How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)

[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]

How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)

[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]

WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year

Related Content

UsernamePublicRestriction

Register

ID043835

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel